A Single Patient Will be Treated With Individual Patient TCR-Transduced PBL
Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
2 other identifiers
expanded_access
N/A
0 countries
N/A
Brief Summary
A single patient will be treated with Individual Patient TCR-Transduced PBL
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 10, 2019
CompletedFirst Posted
Study publicly available on registry
December 11, 2019
CompletedSeptember 4, 2020
September 1, 2020
December 10, 2019
September 3, 2020
Interventions
Eligibility Criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Design
- Study Type
- expanded access
- Sponsor Type
- NIH
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 10, 2019
First Posted
December 11, 2019
Last Updated
September 4, 2020
Record last verified: 2020-09